Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 18.2 15.7 116.1% View Chart
P/BV x 3.9 2.6 153.0% View Chart
Dividend Yield % 0.3 0.4 68.4%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs830712 116.6%   
Low Rs527484 109.0%   
Sales per share (Unadj.) Rs333.9349.6 95.5%  
Earnings per share (Unadj.) Rs40.432.8 123.1%  
Cash flow per share (Unadj.) Rs51.844.3 116.7%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.3 110.1%  
Book value per share (Unadj.) Rs237.1198.6 119.3%  
Shares outstanding (eoy) m585.91282.17 207.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.7 118.9%   
Avg P/E ratio x16.818.2 92.2%  
P/CF ratio (eoy) x13.113.5 97.3%  
Price / Book Value ratio x2.93.0 95.1%  
Dividend payout %6.26.1 101.5%   
Avg Mkt Cap Rs m397,569168,625 235.8%   
No. of employees `00017.912.0 148.3%   
Total wages/salary Rs m25,84920,561 125.7%   
Avg. sales/employee Rs Th10,956.98,196.0 133.7%   
Avg. wages/employee Rs Th1,447.71,708.1 84.8%   
Avg. net profit/employee Rs Th1,324.3768.5 172.3%   
INCOME DATA
Net Sales Rs m195,63698,655 198.3%  
Other income Rs m1,5532,081 74.6%   
Total revenues Rs m197,189100,736 195.7%   
Gross profit Rs m39,51915,858 249.2%  
Depreciation Rs m6,6803,259 204.9%   
Interest Rs m2,6263,346 78.5%   
Profit before tax Rs m31,76711,335 280.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8811,672 -52.7%   
Tax Rs m7,2693,756 193.5%   
Profit after tax Rs m23,6459,250 255.6%  
Gross profit margin %20.216.1 125.7%  
Effective tax rate %22.933.1 69.0%   
Net profit margin %12.19.4 128.9%  
BALANCE SHEET DATA
Current assets Rs m153,64566,968 229.4%   
Current liabilities Rs m120,42940,211 299.5%   
Net working cap to sales %17.027.1 62.6%  
Current ratio x1.31.7 76.6%  
Inventory Days Days13583 162.2%  
Debtors Days Days6481 78.4%  
Net fixed assets Rs m103,90933,322 311.8%   
Share capital Rs m586282 207.6%   
"Free" reserves Rs m138,32255,770 248.0%   
Net worth Rs m138,90856,052 247.8%   
Long term debt Rs m1,80035,738 5.0%   
Total assets Rs m264,544132,888 199.1%  
Interest coverage x13.14.4 298.5%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x0.70.7 99.6%   
Return on assets %9.99.5 104.8%  
Return on equity %17.016.5 103.1%  
Return on capital %23.817.8 133.8%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31662,998 154.5%   
Fx outflow Rs m40,58922,859 177.6%   
Net fx Rs m56,72740,140 141.3%   
CASH FLOW
From Operations Rs m16,22013,242 122.5%  
From Investments Rs m-28,768-6,990 411.6%  
From Financial Activity Rs m19,191-7,387 -259.8%  
Net Cashflow Rs m6,656-2,971 -224.1%  

Share Holding

Indian Promoters % 54.1 48.3 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 6.9 115.2%  
FIIs % 27.7 34.4 80.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 56,727 122.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   TTK HEALTHCARE  ALEMBIC  WYETH  ELDER PHARMA  SUVEN LIFE SCIENCES  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 15, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS